In-depth Dialogue on the "Core Triangle" of Inflammation: How IL-6, IL-1β, and TNF-α Interact to Drive Disease Progression?

Inflammation is a key defense mechanism for maintaining homeostasis and responding to injury, but its dysregulation becomes a critical pathological basis for various chronic diseases. Interleukin-6 (IL-6), Interleukin-1β (IL-1β), and Tumor Necrosis Factor-α (TNF-α) are widely recognized as core pro-inflammatory cytokines central to the inflammatory response, forming crucial hubs within the immune network.

A deep understanding of the molecular network involving IL-6, IL-1β, and TNF-α is of great significance for precise diagnosis and the development of multi-target anti-inflammatory strategies. This article aims to elucidate the molecular mechanisms and pathophysiological roles of these three cytokines in inflammation, exploring their synergistic effects and dynamic balance across different diseases, to assist your research.

1. What are the Core Pro-inflammatory Cytokines?

Inflammation is a vital physiological process for resisting infection, repairing tissue, and maintaining homeostasis. This response eliminates harmful stimuli and promotes tissue repair through complex cellular and molecular events. However, if the inflammatory response persists or becomes dysregulated, it can transform into chronic inflammation, triggering various pathological states such as metabolic disorders, autoimmune diseases, neurodegenerative diseases, and cancer. Studies indicate that the cytokine network plays a central regulatory role in inflammation, with IL-6, IL-1β, and TNF-α being key pro-inflammatory signaling mediators ^[1].

These cytokines are secreted by various immune cells including macrophages, T cells, B cells, and fibroblasts. They activate downstream signaling pathways by binding to specific receptors, thereby regulating immune responses and cell survival. Immune network analysis shows that IL-6, IL-1β, and TNF-α possess the highest centrality in the topological structure, acting as key nodes in maintaining immune system homeostasis ^[2]. Their aberrant activation is closely associated with diseases such as Diabetic Retinopathy (DR), Systemic Lupus Erythematosus (SLE), and Colorectal Cancer (CRC) ^[3-6].

2. Signaling Pathways and Regulation of IL-6, IL-1β, and TNF-α

IL-6, IL-1β, and TNF-α are three core mediators of the inflammatory response. They initiate signaling cascades through specific receptors, activate transcription factors, and regulate the expression of numerous pro-inflammatory genes, thereby driving the inflammatory process. This chapter systematically analyzes their signal transduction mechanisms, mutual regulation, and molecular networks.

2.1 IL-6 Signaling and Effects

IL-6 signaling is primarily mediated through the JAK/STAT3 pathway. After IL-6 binds to membrane-bound or soluble IL-6 receptors (IL-6R), it forms a complex with gp130, inducing gp130 dimerization and activation of JAK family kinases. Subsequently, STAT3 is phosphorylated, dimerizes, and translocates to the nucleus, regulating the expression of acute-phase proteins and inflammation-related genes ^[8].

IL-6 trans-signaling is particularly critical in inflammation regulation. For instance, the IL-6/sIL-6R complex can activate cells lacking membrane-bound IL-6R, enhancing osteoclast differentiation and inflammatory responses ^[9,10]. In the central nervous system, IL-6/sIL-6R can synergize with TNF-α or IL-1β to induce autocrine IL-6 expression in astrocytes ^[11]. Furthermore, miR-223-3p forms a feedback loop by negatively regulating STAT3, and TNF-α can upregulate this miRNA to balance inflammation ^[12,13].

In tumors, aberrant activation of the IL-6/STAT3 axis promotes cancer cell proliferation and metastasis, as observed in prostate and lung cancers where persistent STAT3 phosphorylation occurs ^[8][15]. Viral factors such as KSHV-encoded vIL-6 can also activate the host STAT3 pathway, indicating the important role of this signaling axis in infection-related tumors ^[16].

2.2 IL-1β Signaling and Effects

IL-1β exists as an inactive pro-IL-1β, and its maturation depends on Caspase-1 activation mediated by the NLRP3 inflammasome. The inflammasome, composed of NLRP3, ASC, and Caspase-1, senses stimuli like LPS, ATP, and viruses, promoting the maturation and release of IL-1β and IL-18 ^[17-20].

Mature IL-1β binds to IL-1R, initiating the MyD88-dependent pathway, activating IRAKs and TRAF6 which subsequently trigger the NF-κB and MAPK pathways, inducing the transcription of pro-inflammatory genes such as TNF-α and IL-6 ^[21-24].

In diseases like osteoarthritis, enteritis, and septic cardiomyopathy, IL-1β drives chondrocyte apoptosis, matrix degradation, and myocardial dysfunction ^[19][25][27]. Its regulatory network involves various non-coding RNAs: for example, miR-4701-5p alleviates inflammation by inhibiting HMGA1, while silencing lncRNA HAGLR reduces chondrocyte injury via the miR-130a-3p/JAK1 axis ^[26][27].

Natural products (such as garlic polysaccharides) can significantly reduce levels of IL-1β, IL-6, and TNF-α by inhibiting NF-κB/STAT3 activation ^[14]. These studies reveal the core driving force of IL-1β in the inflammatory cascade and its multi-layered regulatory mechanisms.

2.3 TNF-α Signaling and Effects

TNF-α mediates signal transduction primarily through TNFR1 and TNFR2 receptors, broadly regulating cell survival, apoptosis, and inflammatory responses. Its main pathways include the NF-κB and MAPK activation cascades ^[29-32]. Upon TNFR1 activation, it recruits TRADD, RIP1, and TRAF2, forming a signaling complex and activating the IKK complex. IKKβ phosphorylates IκBα, leading to its degradation, allowing the NF-κB dimer (p65/p50) to translocate to the nucleus and induce the expression of genes like IL-6, IL-1β, and CCL2 ^[30][22]. Simultaneously, TNF-α also regulates inflammation, apoptosis, and stress responses via p38 and JNK ^[24][30].

In Rheumatoid Arthritis (RA), TNF-α activates the NF-κB/MAPK signaling in synovial cells, promoting the release of MMPs and IL-6, thereby driving joint destruction ^[30]; in atherosclerosis, TNF-α, along with MCP-1, participates in early plaque formation ^[34]. Furthermore, it can synergize with IFN-γ to induce a CXCL10⁺ inflammatory macrophage phenotype, revealing shared pathological mechanisms across different inflammatory diseases ^[33]. In intervertebral disc degeneration and xenotransplantation models, persistent TNF-α activation also leads to tissue damage and rejection ^[17][22]. In summary, TNF-α constitutes a core regulatory axis of the inflammatory response through its dual NF-κB and MAPK pathways.

2.4 Integrated Analysis of Cytokine Signaling Pathways

The downstream signaling of IL-6, IL-1β, and TNF-α shows significant crosstalk. IL-1β and TNF-α drive inflammation propagation via NF-κB/MAPK, while IL-6 primarily utilizes the JAK/STAT3 axis to sustain the response. Natural compounds like Ebosin and phytol effectively reduce inflammation by inhibiting IKKβ, p38, and JNK phosphorylation ^[20][28]. This signaling crosstalk provides plasticity to the inflammatory response and offers a theoretical basis for multi-target intervention.

2.5 Crosstalk and Network Regulation Among Cytokines

Mutual induction and feedback regulation among IL-6, IL-1β, and TNF-α construct a complex inflammatory network.

Studies show that IL-1β and TNF-α induce each other and synergistically promote IL-6 expression, forming an inflammation amplification loop ^[7][8][24]. In the nervous system, IL-6/sIL-6R synergizes with IL-1β or TNF-α to upregulate IL-6, creating a positive feedback loop ^[8]. Additionally, IL-1β can induce GRP78 upregulation and promote IL-6 release via p38 MAPK ^[21,22], revealing cross-regulation between inflammatory signaling and cellular stress.

3. Pathophysiological Significance and Disease Associations

Aberrant expression of IL-6, IL-1β, and TNF-α is closely associated with various diseases:

In metabolic diseases, they are synergistically elevated in Diabetic Retinopathy, promoting angiogenesis and neural damage ^[3];
In SLE, their serum levels positively correlate with disease activity ^[4];
In tumors, persistently activated IL-6/STAT3 signaling drives cell proliferation and immune escape ^[10][11];
In infectious diseases and sepsis, NLRP3 inflammasome-driven release of IL-1β/IL-18 exacerbates tissue injury ^[12].

This indicates that these three cytokines form the inflammatory "core triangle," whose dynamic balance is crucial for maintaining immune homeostasis.

4. Therapeutic Strategies and Clinical Prospects

Targeted therapies against IL-6, IL-1β, and TNF-α have achieved breakthroughs in various diseases:

IL-6 blockers (e.g., Tocilizumab) show significant efficacy in Rheumatoid Arthritis and cytokine storms;
IL-1β inhibitors (e.g., Canakinumab) can reduce cardiovascular inflammation;
TNF-α antagonists (e.g., Infliximab, Etanercept) have become standard therapies for inflammatory diseases.

Furthermore, miRNA regulation, inflammasome inhibitors, and multi-target interventions using natural compounds provide directions for the next generation of anti-inflammatory strategies.

5. Summary

IL-6, IL-1β, and TNF-α are central hubs in the inflammatory signaling network, playing key roles in maintaining immune balance and mediating pathological inflammation. Through pathways such as NF-κB, MAPK, and JAK/STAT3, they form a multi-layered, cross-regulatory network. Their precise spatiotemporal expression determines the intensity and persistence of the inflammatory response. Abnormal activation or feedback dysregulation can lead to chronic inflammation, tissue damage, and the onset of various diseases, including metabolic disorders, autoimmune diseases, neuroinflammation, and cancer. Systematically analyzing their signaling pathways and interactions not only deepens the understanding of the molecular mechanisms of inflammation but also provides a theoretical basis for precise anti-inflammatory and multi-target therapies.

It is noteworthy that **the detection of IL-6, IL-1β, and TNF-α is also highly significant in both scientific research and clinical studies**. Quantitative monitoring of the levels of these key inflammatory mediators can be used to assess disease activity, validate inflammation models, monitor treatment responses, and screen for potential biomarkers. Accurate and sensitive detection methods provide reliable data support for basic research and offer early warning evidence for clinical decision-making.

CUSABIO's Inflammatory Factor ELISA Kit Panel now covers multiple core inflammatory factors including IL-6, IL-1β, and TNF-α, helping researchers efficiently assess the molecular characteristics of inflammatory responses and accelerating mechanistic research and translational applications.

References

[1] Paolo Tieri, Silvana Valensin, Vito Latora, Gastone C. Castellani, Massimo Marchiori, Daniel Remondini, Claudio Franceschi.(2004). Quantifying the relevance of different mediators in the human immune cell network.

[2] Sheng-Rong Zou, Yu-Jing Peng, Zhong-Wei Guo, Ta Zhou, Chang-gui Gu, Da-Ren He.(2007). An Empirical Study of Immune System Based On Bipartite Network.

[3] Songfu Feng, Honghua Yu, Ying Yu, Yu Geng, Dongli Li, Chun Yang, Qingjun Lv, Li Lu, Ting Liu, Guodong Li, Ling Yuan.(2018). Levels of Inflammatory Cytokines IL-1β, IL-6, IL-8, IL-17A, and TNF-α in Aqueous Humour of Patients with Diabetic Retinopathy.

[4] V. Umare, V. Pradhan, M. Nadkar, A. Rajadhyaksha, M. Patwardhan, K. Ghosh, A. Nadkarni.(2014). Effect of Proinflammatory Cytokines (IL-6, TNF-α, and IL-1β) on Clinical Manifestations in Indian SLE Patients.

[5] Sheng-Rong Zou, Zhong-Wei Guo, Yu-Jing Peng, Ta Zhou, Chang-Gui Gu, Da-Ren He.(2007). A Brand-new Research Method of Neuroendocrine System.

[6] D. Florescu, M. Boldeanu, Robert-Emmanuel Șerban, L. Florescu, M. Șerbănescu, Mihaela Ionescu, L. Streba, Cristian Constantin, C. Vere.(2023). Correlation of the Pro-Inflammatory Cytokines IL-1β, IL-6, and TNF-α, Inflammatory Markers, and Tumor Markers with the Diagnosis and Prognosis of Colorectal Cancer.

[7] D. Skelly, E. Hennessy, M. Dansereau, C. Cunningham.(2013). A Systematic Analysis of the Peripheral and CNS Effects of Systemic LPS, IL-1Β, TNF-α and IL-6 Challenges in C57BL/6 Mice.

[8] B. Barton, T. Murphy, Patricia V Adem, R. Watson, R. Irwin, Hosea F. S. Huang.(2001). IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells.

[9] S. Kwok, M. Cho, Yang-Mi Her, Hye‐Joa Oh, Mi-Kyung Park, Seon-Yeong Lee, Yun‐Ju Woo, J. Ju, Kyung-Su Park, Ho‐Youn Kim, Sung-Hwan Park.(2012). TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren’s syndrome.

[10] W. Feng, Hongrui Liu, Tingting Luo, Di Liu, Juan Du, Jing Sun, Wei Wang, Xiuchun Han, Kaiyun Yang, Jie Guo, N. Amizuka, Minqi Li.(2017). Combination of IL-6 and sIL-6R differentially regulate varying levels of RANKL-induced osteoclastogenesis through NF-κB, ERK and JNK signaling pathways.

[11] Nicholas J. Van Wagoner, Jae-Wook Oh, P. Repovic, E. Benveniste.(1999). Interleukin-6 (IL-6) Production by Astrocytes: Autocrine Regulation by IL-6 and the Soluble IL-6 Receptor.

[12] E. Helset, T. Sildnes, R. Seljelid, Z. Konopski.(1993). Endothelin-1 stimulates human monocytes in vitro to release TNF-α , IL-1β and IL-6.

[13] Juan Wu, Ping Niu, Yueqiang Zhao, Yan-li Cheng, Weiping Chen, Lan Lin, J. Lu, Xuefeng Cheng, Zhiliang Xu.(2019). Impact of miR-223-3p and miR-2909 on inflammatory factors IL-6, IL-1ß, and TNF-α, and the TLR4/TLR2/NF-κB/STAT3 signaling pathway induced by lipopolysaccharide in human adipose stem cells.

[14] Xin Shao, Jialong Li, Huidan Zhang, Xuhui Zhang, Chongzheng Sun, Ouyang Xin, Yong Wang, Xiyang Wu, Chunbo Chen.(2023). Anti-inflammatory effects and molecular mechanisms of bioactive small molecule garlic polysaccharide.

[15] Xinli Liu, Xu-tao Zhang, Jin Meng, Hong-Fei Zhang, Yong Zhao, Chen Li, Yang Sun, Q. Mei, Feng Zhang, Tao Zhang.(2017). ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways.

[16] J. Osborne, P. Moore, Yuan Chang.(1999). KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways.

[17] Hanchao Gao, Qing Zhang, Jicheng Chen, D. Cooper, H. Hara, Pengfei Chen, Ling Wei, Yanli Zhao, Jia Xu, Zesong Li, Z. Cai, Shaodong Luan, Lisha Mou.(2018). Porcine IL‐6, IL‐1β, and TNF‐α regulate the expression of pro‐inflammatory‐related genes and tissue factor in human umbilical vein endothelial cells.

[18] Sara J Hamis, Fiona R Macfarlane.(2020). A single-cell mathematical model of SARS-CoV-2 induced pyroptosis and the effects of anti-inflammatory intervention.

[19] K. Fujimura, T. Karasawa, T. Komada, N. Yamada, C. Baatarjav, T. Matsumura, H. Mizukami, K. Kario, M. Takahashi.(2023). NLRP3 inflammasome-produced pro-inflammatory cytokines IL-1b and IL-18 are critical exacerbating factors of septic cardiomyopathy.

[20] Shanmuga S. Mahalingam, S. Jayaraman, Adhvika Arunkumar, Holly M. Dudley, Dona Anthony, C. Shive, Jeffrey M. Jacobson, P. Pandiyan.(2023). Distinct SARS-CoV-2 specific NLRP3 and IL-1β responses in T cells of aging patients during acute COVID-19 infection.

[21] Kunjan Khanna, Hui Yan, Muneshwar Mehra, N. Rohatgi, G. Mbalaviele, E. Mellins, R. Faccio.(2023). Tmem178 Negatively Regulates IL‐1β Production Through Inhibition of the NLRP3 Inflammasome.

[22] Gang Gao, F. Chang, Ting Zhang, Xinhu Huang, Chen Yu, Zhixia Hu, Mingming Ji, Yufen Duan.(2019). Naringin Protects Against Interleukin 1β (IL-1β)-Induced Human Nucleus Pulposus Cells Degeneration via Downregulation Nuclear Factor kappa B (NF-κB) Pathway and p53 Expression.

[23] C. Yu, W. Miao, Y. Y. Zhang, M. Zou, X. F. Yan.(2018). Inhibition of miR-126 protects chondrocytes from IL-1β induced inflammation via upregulation of Bcl-2.

[24] O. Krupkova, A. Sadowska, T. Kameda, W. Hitzl, O. Hausmann, Juergen Klasen, K. Wuertz-Kozak.(2018). p38 MAPK Facilitates Crosstalk Between Endoplasmic Reticulum Stress and IL-6 Release in the Intervertebral Disc.

[25] Yongqiang Liu, Qian Li, Zhi-Rui Gao, Fangcao Lei, Xuefeng Gao.(2021). Circ-SPG11 knockdown hampers IL-1β-induced osteoarthritis progression via targeting miR-337-3p/ADAMTS5.

[26] H. Zhang, Cheng Chen, Jie Song.(2022). microRNA-4701-5p protects against interleukin-1β induced human chondrocyte CHON-001 cells injury via modulating HMGA1.

[27] Yunzhou Zuo, Changjun Xiong, X. Gan, Wei Xie, Xiaokang Yan, Yanzhao Chen, Xu-gui Li.(2023). LncRNA HAGLR silencing inhibits IL-1β-induced chondrocytes inflammatory injury via miR-130a-3p/JAK1 axis.

[28] Fang Li, Hua Huang, Ping Zhao, Jie Jiang, Xufeng Ding, Donxgue Lu, Lijiang Ji.(2023). Curculigoside mitigates dextran sulfate sodium-induced colitis by activation of KEAP1-NRF2 interaction to inhibit oxidative damage and autophagy of intestinal epithelium barrier.

[29] Zhen-Tao Mo, Jie Zheng, Yu Liao.(2021). Icariin inhibits the expression of IL-1β, IL-6 and TNF-α induced by OGD/R through the IRE1/XBP1s pathway in microglia.

[30] Yang Zhang, Li-fei Wang, Liping Bai, R. Jiang, Jian-bo Wu, Yuan Li.(2022). Ebosin Attenuates the Inflammatory Responses Induced by TNF-α through Inhibiting NF-κB and MAPK Pathways in Rat Fibroblast-Like Synoviocytes.

[31] P. Pothacharoen, R. Chaiwongsa, Theerawut Chanmee, Orapin Insuan, Thanchanok Wongwichai, Phornpimon Janchai, P. Vaithanomsat.(2021). Bromelain Extract Exerts Antiarthritic Effects via Chondroprotection and the Suppression of TNF-α–Induced NF-κB and MAPK Signaling.

[32] Alexandra M S Carvalho, Luana Heimfarth, E. W. Pereira, Fabrício S Oliveira, I. A. Menezes, H. Coutinho, Laurent Picot, Â. Antoniolli, J. Quintans, L. Quintans-Júnior.(2020). Phytol, a Chlorophyll Component, Produces Antihyperalgesic, Anti-inflammatory, and Antiarthritic Effects: Possible NFκB Pathway Involvement and Reduced Levels of the Proinflammatory Cytokines TNF-α and IL-6.

[33] Fan Zhang, Joseph R. Mears, L. Shakib, Jessica I. Beynor, Sara Shanaj, I. Korsunsky, A. Nathan, L. Donlin, S. Raychaudhuri.(2021). IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation.

[34] Abdush Salam Pramanik, Bibaswan Dey, G. P. Raja Sekhar.(2023). A Two-Phase Model of Early Atherosclerotic Plaque Development with LDL Toxicity Effects.